This study is looking at a new medicine called neladalkib, which is being compared to another medicine, alectinib, for patients who have a special kind of lung cancer called ALK-positive NSCLC (Non-Small Cell Lung Cancer). ALK-positive means that the cancer cells have a specific change in a protein called Anaplastic Lymphoma Kinase. The study wants to see if neladalkib helps patients live longer without their cancer getting worse, which is called progression-free survival (PFS).

• Participation: Around 450 patients will join, and they will be randomly given either neladalkib or alectinib.
• Eligibility: Only those without previous treatments for this lung cancer can join, and they must have a specific ALK change in their cancer.
• Exclusions: Patients must not have certain other health conditions, allergies, or recent major surgeries.

The study will help doctors understand if neladalkib is a better choice for treating this type of lung cancer compared to alectinib.